KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly refractory large B-cell lymphoma, new research shows.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/lymphoma-dual-targeting-car-t-shows-safety-efficacy-2025a1000fwg?src=rss
Author :
Publish date : 2025-06-13 12:37:00
Copyright for syndicated content belongs to the linked Source.
